RWEOne Expands Asia-Pacific Site Network to 18 New Countries

Expansion establishes RWEOne as a leading Real-World Evidence (RWE) provider with on-the-ground coverage across APAC for rapid rare disease oncology investigator activation.

FOR IMMEDIATE RELEASE

Singapore — July 28, 2026 — RWEOne, a specialized clinical technology and services partner empowering global pharmaceutical companies with end-to-end Real-World Evidence (RWE) and Real-World Data (RWD) studies, today announced the expansion of its Global Site Network to 18 additional Asia-Pacific (APAC) countries. The expanded network gives biopharmaceutical sponsors access to on-the-ground investigators, patient advocacy partnerships, and rare disease specialty centers across the region.

Expansion Details

The APAC network expansion adds investigator sites and key markets including Singapore, South Korea, Taiwan, Hong Kong SAR, Malaysia, Thailand, Vietnam, Philippines, Indonesia, India, Bangladesh, Pakistan, Australia, New Zealand, and select Greater China partnerships. On-the-ground operations teams will support regulatory-compliant study conduct.

• 412 pre-qualified investigators in oncology, rare disease, and cardiovascular
• 38 specialty rare-disease reference centers with patient advocacy partnerships
• Local IRB/IEC relationships for fast study start-up in each country
• Regulatory and local-language support across 12 APAC languages

A Quote from Leadership

This APAC expansion directly answers what sponsors consistently ask us for: true, on-the-ground site capability in complex Asian markets — especially for ultra-rare indications where patient access and site relationships can make or break a study.

About RWEOne

RWEOne is a specialized clinical technology and services partner empowering global pharmaceutical companies to conduct end-to-end Real-World Evidence (RWE) and Real-World Data (RWD) studies. Backed by 12+ years of clinical expertise, RWEOne integrates artificial intelligence with existing healthcare data endpoints to compress clinical study lifecycles, validate data in real-time, and drive confident regulatory and commercial decisions.

Media Contact:
RWEOne Press Office
[email protected]